Overview

AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Saracatinib